MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Ardelyx, Inc (NASDAQ: ARDX)*
Organization & Developments: Ardelyx
Parents
Ardelyx, Inc (NASDAQ: ARDX)*
Children
*Ardelyx develops therapeutics acting exclusively in the gastrointestinal tract and devoid of systemic exposure.
*Biopharmaceutical that is researching medicines to treat kidney diseases, irritable bowel syndrome (IBS-C), and other diseases
*The company's drug candidates target important diseases, as well as pathologies with a specific inflammatory pathway.
2017: Ardelyx (ARDX) Reports Positive T3MPO-2 Phase 3 Trial Results in IBS-C - Slideshow_seekingalpha
2017: Ardelyx rises on better IBS data and a clearer path to FDA filing
2018: Ardelyx Looks Cheap But Not Without Risk - Ardelyx (NASDAQ:ARDX)
2019: Ardelyx’s lead drug tenapanor scores in second hyperphosphatemia study, shares leap – Endpoints News
2020: Ardelyx Is An Even Bigger Value After Recent Sell-Off
2020: Biotech Analysis Central Preview Series: Ardelyx, Inc.
2020: Giving The 'Thumbs Up' On Ardelyx
2020: Reassessing Ardelyx
2021: Ardelyx Before The April PDUFA
2021: Ardelyx craters after FDA stuns analysts and rejects their kidney disease pitch
2021: Ardelyx: Indecisive Regulators, Frustrated Company, Gruelling Wait For Investors
2021: Ardelyx: Second Opportunity
2022: Ardelyx: Big Transitional Period_seekingalpha.com
2022: Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position_seekingalpha.com
2022: Ardelyx: The Journey Continues_seekingalpha.com
2023: Ardelyx Is Beginning To Look Highly Interesting Again_ seekingalpha.com
2023: Ardelyx: XPHOZAH Is No Niche Product_
2024: Ardelyx Faces Rising Challenges Despite Revenue Growth
2024: Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
2024: Ardelyx Shrugs Off 'Mixed' Q4 Earnings
2024: Ardelyx Stock Alert: Court Dismisses CMS Lawsuit, XPHOZAH Access Concerns Mount
2024: Ardelyx sues CMS about plan to place phosphate binders into ESRD payment bundle
2024: Ardelyx sues US health department over kidney disease drug
2024: Ardelyx: A Small Bet Its Latest Setback Will Be Temporary
2024: Ardelyx: Despite Decent Uptake, We Need More Clarity On The Lawsuit_seekingalpha.com
2024: Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement_ seekingalpha.com
2024: Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
2024: Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability_seekingalpha.com
2024: Ardelyx's XPHOZAH Still An Afterthought To The Pros
2025: Uncertain Growth Ahead (Downgrade)
Jumps
*Key People: Ardelyx
Finance & Acquisitions: Ardelyx